DOCSLIB.ORG

Hepatic Metabolic Regulation by Nuclear Factor E4BP4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hepatic Metabolic Regulation by Nuclear Factor E4BP4 66 1 Journal of Molecular Z Zhao et al. E4BP4 regulates liver metabolic 66:1 R15–R21 Endocrinology processes REVIEW Hepatic metabolic regulation by nuclear factor E4BP4 Zifeng Zhao1,2, Lei Yin2, Feihua Wu1 and Xin Tong2 1Department of Pharmacology of Chinese Materia Medica, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China 2Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, USA Correspondence should be addressed to F Wu or X Tong: [email protected] or [email protected] Abstract Discovered as a b-ZIP transcription repressor 30 years ago, E4 promoter-binding protein 4 Key Words (E4BP4) has been shown to play critical roles in immunity, circadian rhythms, and cancer f E4BP4 progression. Recent research has highlighted E4BP4 as a novel regulator of metabolisms f insulin in various tissues. In this review, we focus on the function and mechanisms of hepatic f lipid E4BP4 in regulating lipid and glucose homeostasis, bile metabolism, as well as xenobiotic f glucose metabolism. Finally, E4BP4-specific targets will be discussed for the prevention and f metabolism treatment of metabolic disorders. Journal of Molecular Endocrinology (2021) 66, R15–R21 Introduction The PAR proteins, named after the conserved proline- repressor with its repression activity primarily located and acid-rich (PAR) domains in a subset of basic leucine in its C-terminal region (Cowell & Hurst 1994) (Fig. 1). zipper (b-ZIP) transcription factors, consist of four family Although Northern blotting analysis indicates the E4bp4 members, TEF/VBP, HLF, DBP, and E4BP4 (Cowell & Hurst mRNA was ubiquitously expressed in various cell lines and 1994). The PAR family proteins form homodimers or mouse tissues, very low abundance of the E4BP4 protein hetero-dimerize within other family proteins and function was detected in most cases, suggesting that the E4BP4 as either transcription activators or repressors (Hai & protein level is likely controlled at both the translational Hartman 2001). The PAR family proteins have been found and post-translational levels (Chen et al. 1995). to have diverse physiological functions in mammals, One of the best-known biological functions of E4BP4 including circadian rhythms, immunoregulation, and is related to immunomodulation (Male et al. 2012). The cancer development (Green 2016). This review will focus E4bp4 promoter was found to be activated by interleukin on the role of E4 promoter-binding protein 4 (E4BP4), 3 in T lymphocytes, giving rise to its other name NF-IL3 also named as nuclear factor, interleukin 3 regulated (Zhang et al. 1995). Subsequently, multiple studies (NFIL3), the least known PAR transcription factor, in have illuminated the essential role of E4BP4 in NK cell liver metabolic regulation. NFIL3/E4BP4 was initially development/maturation as well as the development of cloned as a b-ZIP transcription factor that binds to the innate lymphoid cells (ILC) (Geiger et al. 2014). E4BP4 consensus sequence (G/A)T(G/T)A(C/T)GTAA(C/T) in the also functions as a key regulator of IL 3-dependent pro-B adenoviral E4 promoter DNA (Cowell et al. 1992). Further lymphocyte survival and immunoglobulin class switch analysis revealed that E4BP4 functions as a transcription (Ikushima et al. 1997). Moreover, E4BP4 was shown to https://jme.bioscientifica.com © 2021 Society for Endocrinology https://doi.org/10.1530/JME-20-0239 Published by Bioscientifica Ltd. Printed in Great Britain Downloaded from Bioscientifica.com at 10/01/2021 08:23:15AM via free access -20-0239 Journal of Molecular Z Zhao et al. E4BP4 regulates liver metabolic 66:1 R16 Endocrinology processes For instance, SREBP-1c, FXR, and ChREBP have been identified as critical transcription factors in lipid and bile acid biosynthesis during feeding (Chiang 2013, Wang et al. 2015), whereas FOXO1, CREB, and PPARα are Figure 1 required in gluconeogenesis and lipid oxidation during Schematic of E4BP4 functional domains. A full color version of this figure fasting (Rui 2014, Wang et al. 2016). Although the E4bp4 is available at https://doi.org/10.1530/JME-20-0239. expression was shown to be most abundant in the liver, regulate cytokine production and the effector functions the regulation of its mRNA by nutrients and hormone in a subsets of T lymphocytes (Kashiwada et al. 2011). signaling has been largely uncharacterized. Our lab has Given its broad actions in multiple immune cells, it discovered that refeeding induces the E4bp4 mRNA and was speculated that E4BP4 might be relevant in human protein in the mouse liver (Tong et al. 2010). We also immune disorders. Indeed, E4BP4 has been reported to be found that insulin potently induces E4bp4 expression implicated in the pathogenesis of IBD, MS, and systemic through the AKT/mTORC1/SREBP-1c pathway (Tong lupus erythematosis (Yin et al. 2017). et al. 2016). Most recently, we reported that chemical or As a protein wearing multiple hats, E4BP4 has also diet-induced ER stress potently induces hepatic E4BP4 to been identified as a key circadian output oscillator in the promote lipid accumulation via the suppression of AMPK molecular circadian clock system. In its core, the circadian pathway (Yang et al. 2020). Altogether, these data suggest clock comprises a transcription-translational feedback that E4BP4 could be a critical player during anabolic loop driven by key circadian proteins including BMAL1, metabolism. CLOCK, PERIOD, CRY, and nuclear receptors (NR1D1 and RORs) (Partch et al. 2014). The E4bp4 mRNA expression was E4BP4 in lipid metabolism shown to display a classical circadian oscillation pattern that was blunted in the Bmal1−/− mice, supporting that E4BP4 and FGF21-promoted fatty acid oxidation E4bp4 is a direct output gene of the molecular circadian During fasting, liver turns on lipolysis to break down clock (Chen et al. 2019b). E4BP4 was also found to triglycerides to release free fatty acids (FFAs) for fatty acid interact with the core clock protein CRY2 in cultured cells oxidation and ATP production inside the mitochondria (Ohno et al. 2007). However, deletion of E4bp4 showed (Rui 2014). The nuclear receptor PPARα plays a dominant little impact on the oscillations of core clock genes. Most role in activating fatty acid oxidation genes in the recently, the Lazar group has shown that the rhythmic liver during fasting (Bougarne et al. 2018). Pparα−/− expression of E4bp4 was disrupted in Kupffer cells from mice were shown to develop liver steatosis along with the liver of adult hepatocyte-specificRev- erbα and Rev-erbβ the suppression of FAO gene expression under food double knockout mice, highlighting an essential role of deprivation (Sugden et al. 2002, Lee et al. 2004, Bougarne the hepatic clock in coordinating metabolic events in the et al. 2018). One of the PPARα targets is FGF21, a hepatic liver (Guan et al. 2020). Given the extensive expression of hormone critical for energy mobilization during fasting E4BP4 in a variety of tissues, it is likely that E4BP4 may (Badman et al. 2007, Inagaki et al. 2007). Once released control a subset of circadian output genes in a tissue- from liver, FGF21 can stimulate adipocyte lipolysis in specific manner. white and brown adipose tissues and increase the levels of FFAs in circulation. We observed that E4BP4 represses the Fgf21 expression in a circadian fashion in hepatocytes. E4BP4 in liver metabolism The Fgf21 mRNA oscillations were anti-phase to those Liver is the central organ in charge of metabolic of E4bp4 during a circadian cycle in the mouse liver homeostasis in mammals. During the cycles of food (Tong et al. 2010). We also detected a drastic decrease in intake, liver turns on anabolic metabolism upon feeding the level of FGF21 in the medium from primary mouse and switches to catabolic metabolism during fasting (Rui hepatocytes transduced with Ad-E4bp4. Our chromatin 2014). This switch between different metabolic pathways immunoprecipitation (CHIP) assay uncovered the direct is tightly controlled at both the transcriptional and binding of E4BP4 to the Fgf21 promoter, consistent post-translational levels. A panel of transcription factors with its potent repression of the Fgf21 expression in sensitive to the nutrient status have been identified as hepatocytes. We further confirmed the physiological critical regulators in maintaining metabolic homeostasis role of E4BP4 as a suppressor of FGF21 in hepatocytes in the liver (Wang et al. 2016, Hatting et al. 2018). in response to insulin. Later on, we reported that G9a, https://jme.bioscientifica.com © 2021 Society for Endocrinology https://doi.org/10.1530/JME-20-0239 Published by Bioscientifica Ltd. Printed in Great Britain Downloaded from Bioscientifica.com at 10/01/2021 08:23:15AM via free access Journal of Molecular Z Zhao et al. E4BP4 regulates liver metabolic 66:1 R17 Endocrinology processes a histone methyl-transferase, is required to mediate E4BP4 in glucose metabolism the suppression of FGF21 by E4BP4 in hepatocytes Liver is also critical for maintaining glucose homeostasis (Tong et al. 2013). In contrast, CREBH, an ER-sensitive (Rui 2014). After food intake, liver synthesizes transcription factor, has been shown to facilitate the glycogen and inhibits gluconeogenesis. In contrast, PPARα-stimulated Fgf21 expression in the liver during liver undergoes glycogenolysis and gluconeogenesis fasting (Zheng et al. 2016). The Zhang group reported to maintain blood glucose level during fasting. These that E4BP4 interacts with CREBH and antagonizes the metabolic processes are tightly controlled by a panel of CREBH-mediated activation of FGF21 in the liver (Zheng hormonal and nutritional signals (Rui 2014, Petersen et al. 2016, Bhattacharya et al. 2018). Collectively, these et al. 2017). Insulin promotes glycogen synthesis results suggest that E4BP4 might contribute to catabolism mainly by stimulating the phosphorylation of GSK3 of lipids by suppressing hepatic FGF21 in response to and inhibits gluconeogenesis by enhancing the FOXO1 insulin during feeding. phosphorylation (Lee & Dong 2017, Bergman et al.
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Regulation of Xenobiotic and Bile Acid Metabolism by the Anti-Aging Intervention Calorie Restriction in Mice
    REGULATION OF XENOBIOTIC AND BILE ACID METABOLISM BY THE ANTI-AGING INTERVENTION CALORIE RESTRICTION IN MICE By Zidong Fu Submitted to the Graduate Degree Program in Pharmacology, Toxicology, and Therapeutics and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Dissertation Committee ________________________________ Chairperson: Curtis Klaassen, Ph.D. ________________________________ Udayan Apte, Ph.D. ________________________________ Wen-Xing Ding, Ph.D. ________________________________ Thomas Pazdernik, Ph.D. ________________________________ Hao Zhu, Ph.D. Date Defended: 04-11-2013 The Dissertation Committee for Zidong Fu certifies that this is the approved version of the following dissertation: REGULATION OF XENOBIOTIC AND BILE ACID METABOLISM BY THE ANTI-AGING INTERVENTION CALORIE RESTRICTION IN MICE ________________________________ Chairperson: Curtis Klaassen, Ph.D. Date approved: 04-11-2013 ii ABSTRACT Calorie restriction (CR), defined as reduced calorie intake without causing malnutrition, is the best-known intervention to increase life span and slow aging-related diseases in various species. However, current knowledge on the exact mechanisms of aging and how CR exerts its anti-aging effects is still inadequate. The detoxification theory of aging proposes that the up-regulation of xenobiotic processing genes (XPGs) involved in phase-I and phase-II xenobiotic metabolism as well as transport, which renders a wide spectrum of detoxification, is a longevity mechanism. Interestingly, bile acids (BAs), the metabolites of cholesterol, have recently been connected with longevity. Thus, this dissertation aimed to determine the regulation of xenobiotic and BA metabolism by the well-known anti-aging intervention CR. First, the mRNA expression of XPGs in liver during aging was investigated.
    [Show full text]
  • Type of the Paper (Article
    Supplementary Material A Proteomics Study on the Mechanism of Nutmeg-induced Hepatotoxicity Wei Xia 1, †, Zhipeng Cao 1, †, Xiaoyu Zhang 1 and Lina Gao 1,* 1 School of Forensic Medicine, China Medical University, Shenyang 110122, P. R. China; lessen- [email protected] (W.X.); [email protected] (Z.C.); [email protected] (X.Z.) † The authors contributed equally to this work. * Correspondence: [email protected] Figure S1. Table S1. Peptide fraction separation liquid chromatography elution gradient table. Time (min) Flow rate (mL/min) Mobile phase A (%) Mobile phase B (%) 0 1 97 3 10 1 95 5 30 1 80 20 48 1 60 40 50 1 50 50 53 1 30 70 54 1 0 100 1 Table 2. Liquid chromatography elution gradient table. Time (min) Flow rate (nL/min) Mobile phase A (%) Mobile phase B (%) 0 600 94 6 2 600 83 17 82 600 60 40 84 600 50 50 85 600 45 55 90 600 0 100 Table S3. The analysis parameter of Proteome Discoverer 2.2. Item Value Type of Quantification Reporter Quantification (TMT) Enzyme Trypsin Max.Missed Cleavage Sites 2 Precursor Mass Tolerance 10 ppm Fragment Mass Tolerance 0.02 Da Dynamic Modification Oxidation/+15.995 Da (M) and TMT /+229.163 Da (K,Y) N-Terminal Modification Acetyl/+42.011 Da (N-Terminal) and TMT /+229.163 Da (N-Terminal) Static Modification Carbamidomethyl/+57.021 Da (C) 2 Table S4. The DEPs between the low-dose group and the control group. Protein Gene Fold Change P value Trend mRNA H2-K1 0.380 0.010 down Glutamine synthetase 0.426 0.022 down Annexin Anxa6 0.447 0.032 down mRNA H2-D1 0.467 0.002 down Ribokinase Rbks 0.487 0.000
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Hanna Joleen 2018 Thesis.Pdf
    Validation of an In Vitro Mutagenicity Assay Based on Pulmonary Epithelial Cells from the Transgenic MutaMouse: Intra-Laboratory Variability and Metabolic Competence By: Joleen Hanna, B.Sc. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science In Biology Specializing in Chemical and Environmental Toxicology Supervisor: Dr. Paul White (University of Ottawa) Thesis Advisory Committee: Dr. Frances Pick (University of Ottawa) Dr. Iain Lambert (Carleton University) University of Ottawa Ontario, Canada March 2018 © Joleen Hanna, Ottawa, Canada, 2018 Abstract: Genetic toxicity tests used for regulatory screening must be rigorously validated to ensure accuracy, reliability and relevance. Hence, prior to establishment of an internationally- accepted test guideline, a new assay must undergo multi-stage validation. An in vitro transgene mutagenicity assay based on an immortalized cell line derived from MutaMouse lung (i.e., FE1 cells) is currently undergoing formal validation. FE1 cells retain a lacZ transgene in a λgt10 shuttle vector that can be retrieved for scoring of chemically-induced mutations. This work contributes to validation of the in vitro transgene (lacZ) mutagenicity assay in MutaMouse FE1 cells. More specifically, the work includes an intra-laboratory variability study, and a follow-up study to assess the endogenous metabolic capacity of FE1 cells. The former is essential to determine assay reliability, the latter to define the range of chemicals that can be reliably screened without an exogenous metabolic activation mixture (i.e., rat liver S9). The intra- laboratory variability assessment revealed minimal variability; thus, assay reproducibility can be deemed acceptable. Assessment of metabolic capacity involved exposure of FE1 cells to 5 known mutagens, and subsequent assessment of changes in the expression of genes involved in xenobiotic metabolism; induced transgene mutant frequency (±S9) was assessed in parallel.
    [Show full text]
  • FMO3) As a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity Swetha Rudraiah University of Connecticut - Storrs, [email protected]
    University of Connecticut OpenCommons@UConn Doctoral Dissertations University of Connecticut Graduate School 8-4-2014 Characterization of Flavin-containing Monooxygenase-3 (FMO3) as a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity Swetha Rudraiah University of Connecticut - Storrs, [email protected] Follow this and additional works at: https://opencommons.uconn.edu/dissertations Recommended Citation Rudraiah, Swetha, "Characterization of Flavin-containing Monooxygenase-3 (FMO3) as a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity" (2014). Doctoral Dissertations. 506. https://opencommons.uconn.edu/dissertations/506 Characterization of Flavin-containing Monooxygenase-3 (FMO3) as a Novel Genetic Determinant of Acetaminophen (APAP) Induced Hepatotoxicity Swetha Rudraiah, Ph.D. University of Connecticut, 2014 Mice pretreated with a mild toxic dose of acetaminophen (APAP) acquire resistance to a second, higher APAP dose. This phenomenon is termed APAP autoprotection and the exact mechanism by which such resistance develops is not clearly known. Given the prevalence of APAP- hepatotoxicity and the human health impact of this potentially hepatotoxic agent, a further understanding of the mechanism(s) involved in such protection are of considerable significance and could lead to new modalities of treatment of acute drug-induced liver injury. The work presented in this thesis investigates FMO3 gene expression during APAP-induced liver injury as well as the functional significance of FMO3 over-expression during APAP- induced liver injury. Furthermore, FMO3 gene regulation during oxidative stress conditions is also examined. Acetaminophen treatment resulted in up-regulation of liver Fmo3 protein in male mice. Female mice express higher liver Fmo3 than males and are highly resistant to APAP hepatotoxicity.
    [Show full text]
  • Consequences of Exchanging Carbohydrates for Proteins in the Cholesterol Metabolism of Mice Fed a High-Fat Diet
    Consequences of Exchanging Carbohydrates for Proteins in the Cholesterol Metabolism of Mice Fed a High-fat Diet Fre´de´ ric Raymond1.¤a, Long Wang2., Mireille Moser1, Sylviane Metairon1¤a, Robert Mansourian1, Marie- Camille Zwahlen1, Martin Kussmann3,4,5, Andreas Fuerholz1, Katherine Mace´ 6, Chieh Jason Chou6*¤b 1 Bioanalytical Science Department, Nestle´ Research Center, Lausanne, Switzerland, 2 Department of Nutrition Science and Dietetics, Syracuse University, Syracuse, New York, United States of America, 3 Proteomics and Metabonomics Core, Nestle´ Institute of Health Sciences, Lausanne, Switzerland, 4 Faculty of Science, Aarhus University, Aarhus, Denmark, 5 Faculty of Life Sciences, Federal Institute of Technology, Lausanne, Switzerland, 6 Nutrition and Health Department, Nestle´ Research Center, Lausanne, Switzerland Abstract Consumption of low-carbohydrate, high-protein, high-fat diets lead to rapid weight loss but the cardioprotective effects of these diets have been questioned. We examined the impact of high-protein and high-fat diets on cholesterol metabolism by comparing the plasma cholesterol and the expression of cholesterol biosynthesis genes in the liver of mice fed a high-fat (HF) diet that has a high (H) or a low (L) protein-to-carbohydrate (P/C) ratio. H-P/C-HF feeding, compared with L-P/C-HF feeding, decreased plasma total cholesterol and increased HDL cholesterol concentrations at 4-wk. Interestingly, the expression of genes involved in hepatic steroid biosynthesis responded to an increased dietary P/C ratio by first down- regulation (2-d) followed by later up-regulation at 4-wk, and the temporal gene expression patterns were connected to the putative activity of SREBF1 and 2.
    [Show full text]
  • Folliculin Regulates Mtorc1/2 and WNT Pathways in Early Human Pluripotency
    ARTICLE https://doi.org/10.1038/s41467-018-08020-0 OPEN Folliculin regulates mTORC1/2 and WNT pathways in early human pluripotency J. Mathieu1,2,3, D. Detraux1,2,8, D. Kuppers4, Y. Wang2,5, C. Cavanaugh2,3, S. Sidhu1,2,S.Levy1,2, A.M. Robitaille2,6, A. Ferreccio1,2, T. Bottorff1,2, A. McAlister1,2, L. Somasundaram1,2, F. Artoni1,2, S. Battle2,7, R.D. Hawkins2,7, R.T. Moon2,6, C.B. Ware2,3, P.J. Paddison2,4 & H. Ruohola-Baker 1,2 To reveal how cells exit human pluripotency, we designed a CRISPR-Cas9 screen exploiting 1234567890():,; the metabolic and epigenetic differences between naïve and primed pluripotent cells. We identify the tumor suppressor, Folliculin(FLCN) as a critical gene required for the exit from human pluripotency. Here we show that FLCN Knock-out (KO) hESCs maintain the naïve pluripotent state but cannot exit the state since the critical transcription factor TFE3 remains active in the nucleus. TFE3 targets up-regulated in FLCN KO exit assay are members of Wnt pathway and ESRRB. Treatment of FLCN KO hESC with a Wnt inhibitor, but not ESRRB/FLCN double mutant, rescues the cells, allowing the exit from the naïve state. Using co-immunoprecipitation and mass spectrometry analysis we identify unique FLCN binding partners. The interactions of FLCN with components of the mTOR pathway (mTORC1 and mTORC2) reveal a mechanism of FLCN function during exit from naïve pluripotency. 1 Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. 2 Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA.
    [Show full text]
  • Supplementary Material
    Table S1 . Genes up-regulated in the CL of stimulated in relation to control animals ( 1.5 fold, P ≤ 0.05). UniGene ID Gene Title Gene Symbol fold change P value Bt.16350.2.A1_s_at guanylate binding protein 5 GBP5 4.42 0.002 Bt.2498.2.A1_a_at fibrinogen gamma chain FGG 3.81 0.002 Bt.440.1.S1_at neurotensin NTS 3.74 0.036 major histocompatibility complex, class I, A /// major Bt.27760.1.S1_at histocompatibility complex, class I, A BoLA /// HLA-A 3.56 0.022 Bt.146.1.S1_at defensin, beta 4A DEFB4A 3.12 0.002 Bt.7165.1.S1_at chemokine (C-X-C motif) ligand 5 CXCL5 3.06 0.031 Bt.15731.1.A1_at V-set and immunoglobulin domain containing 4 VSIG4 3.03 0.047 Bt.22869.1.S2_at fatty acid binding protein 5 (psoriasis-associated) FABP5 3.02 0.006 Bt.4604.1.S1_a_at acyl-CoA synthetase medium-chain family member 1 ACSM1 2.93 0.001 Bt.6406.1.S3_at CCAAT/enhancer binding protein (C/EBP), delta CEBPD 2.92 0.011 Bt.19845.2.A1_at coagulation factor XIII, A1 polypeptide F13A1 2.83 0.005 Bt.209.3.S1_at lysozyme (renal amyloidosis) LYZ 2.77 0.0003 Bt.15908.1.S1_at methyltransferase like 7A METTL7A 2.59 0.007 Bt.28383.1.S1_at granulysin GNLY 2.58 0.034 Bt.20455.1.S1_at Microtubule-associated protein tau MAPT 2.56 0.047 Bt.6556.1.S1_at regakine 1 LOC504773 2.55 0.011 Bt.11259.1.S1_at putative ISG12(a) protein ISG12(A) 2.55 0.037 Bt.28243.1.S1_a_at vanin 1 VNN1 2.54 0.008 Bt.405.1.S1_at follistatin FST 2.52 0.002 Bt.9510.2.A1_a_at T-cell immunoglobulin and mucin domain containing 4 TIMD4 2.47 0.024 Bt.499.1.S1_a_at prolactin receptor PRLR 2.44 0.010 serpin peptidase
    [Show full text]
  • Preliminary Scientific Program*
    ABSTRACTS FROM THE 22ND NORTH AMERICAN ISSX MEETING July 15 - 19, 2018 Montréal, Canada 22nd North American ISSX Meeting July 15 - 19, 2018 Montréal, Canada Contents Sunday, July 15, 2018 Short Course 1: Model Systems and Methods for Assessing Uptake and Efflux of Small Molecules 3 Abstracts: SC1.1 - S1.4 Short Course 2: Enzyme Induction and Regulatory Guidance 4 Abstracts: S2.1 - SC2.4 Short Course 3: In silico Modeling of in vitro Metabolism, Transport, and Toxicity Data 5 Abstracts: SC3.1 - SC3.6 Short Course 4: Immunotoxicology 8 Abstracts: SC4.1 - SC4.4 Keynote Lecture: Immuno Oncology State-of-the-Field and How it Helps Understand the Immune System and Mechanisms for Drug Efficacy and Toxicity 9 Abstract: S1 Monday, July 16, 2018 Plenary Lecture 1: Intracellular Drug Concentrations: Theory, Practice, and Promise 9 Abstract: S2 Parallel Symposium 1: Transporters as Determinants of Target Organ Toxicities 10 Abstracts: S3 - S6 Parallel Symposium 2: Development of Guidelines to Implement Pharmacogenomics-based Clinical Decision 11 Abstracts: S7 - S10 Selected New Investigator Abstract Presentations 43, 46, 47, 95, 97, 107, 114, 129 Abstracts: P5, P12, P13, P110, P114, P135, P150, and P180 Pre-doctoral/Graduate Poster Awards Finalist Poster Presentations 34 Abstracts: A1 - A6 Poster Presentation Session 1 42 Abstracts: P1 - P62 Tuesday, July 17, 2018 Plenary Lecture 2: Novel Synthetic and Computational Approaches to the Discovery of Drugs Targeting 12 Abstract: S11 Parallel Symposium 3: The Impact of Pregnancy on Xenobiotic Disposition
    [Show full text]
  • Methods and Compositions for the Treatment of Non-Small Cell Lung Cancer
    (19) TZZ_¥_T (11) EP 1 743 947 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12Q 1/68 (2006.01) C12N 15/12 (2006.01) 11.01.2012 Bulletin 2012/02 G01N 33/50 (2006.01) C12N 15/11 (2006.01) A61P 35/00 (2006.01) A61K 39/00 (2006.01) (21) Application number: 06022167.8 (22) Date of filing: 22.09.2003 (54) Methods and compositions for the treatment of non-small cell lung cancer Verfahren und Zusammensetzungen zur Behandlung von nichtkleinzelligem Lungenkrebs Méthodes et compositions pour le traitement du cancer du poumon "non à petites cellules" (84) Designated Contracting States: (60) Divisional application: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 10010306.8 / 2 264 185 HU IE IT LI LU MC NL PT RO SE SI SK TR 10010307.6 / 2 264 186 10010308.4 / 2 264 187 (30) Priority: 30.09.2002 US 414673 P 10010309.2 / 2 264 190 28.02.2003 US 451374 P 10010310.0 / 2 264 457 28.04.2003 US 466100 P 10010311.8 / 2 278 028 10010312.6 / 2 270 498 (43) Date of publication of application: 10010313.4 / 2 270 499 17.01.2007 Bulletin 2007/03 10010314.2 / 2 270 500 10010315.9 / 2 270 501 10010316.7 / 2 270 502 10010317.5 / 2 270 503 10010318.3 / 2 270 210 10010319.1 / 2 270 211 10010320.9 / 2 270 212 10010321.7 / 2 270 213 10010322.5 / 2 270 214 10010323.3 / 2 270 215 10010324.1 / 2 270 216 10010325.8 / 2 270 217 10010326.6 / 2 270 218 10010327.4 / 2 270 219 10010328.2 / 2 270 220 10010329.0 / 2 270 221 10010330.8 / 2 270 222 10010331.6 / 2 270 223 10010332.4 / 2 270 224 10010333.2 / 2 270 225 (62) Document number(s) of the earlier application(s) in accordance with Art.
    [Show full text]
  • Supplemental Figures 04 12 2017
    Jung et al. 1 SUPPLEMENTAL FIGURES 2 3 Supplemental Figure 1. Clinical relevance of natural product methyltransferases (NPMTs) in brain disorders. (A) 4 Table summarizing characteristics of 11 NPMTs using data derived from the TCGA GBM and Rembrandt datasets for 5 relative expression levels and survival. In addition, published studies of the 11 NPMTs are summarized. (B) The 1 Jung et al. 6 expression levels of 10 NPMTs in glioblastoma versus non‐tumor brain are displayed in a heatmap, ranked by 7 significance and expression levels. *, p<0.05; **, p<0.01; ***, p<0.001. 8 2 Jung et al. 9 10 Supplemental Figure 2. Anatomical distribution of methyltransferase and metabolic signatures within 11 glioblastomas. The Ivy GAP dataset was downloaded and interrogated by histological structure for NNMT, NAMPT, 12 DNMT mRNA expression and selected gene expression signatures. The results are displayed on a heatmap. The 13 sample size of each histological region as indicated on the figure. 14 3 Jung et al. 15 16 Supplemental Figure 3. Altered expression of nicotinamide and nicotinate metabolism‐related enzymes in 17 glioblastoma. (A) Heatmap (fold change of expression) of whole 25 enzymes in the KEGG nicotinate and 18 nicotinamide metabolism gene set were analyzed in indicated glioblastoma expression datasets with Oncomine. 4 Jung et al. 19 Color bar intensity indicates percentile of fold change in glioblastoma relative to normal brain. (B) Nicotinamide and 20 nicotinate and methionine salvage pathways are displayed with the relative expression levels in glioblastoma 21 specimens in the TCGA GBM dataset indicated. 22 5 Jung et al. 23 24 Supplementary Figure 4.
    [Show full text]